The ceramide heart failure score provided favorable risk reclassification for combined endpoint and all-cause motility beyond traditional ADHERE and BNP levels [net reclassification improvement, 0.42 (95% CI: 0.13–0.70) and 0.49 (95% CI: 0.20–0.78), respectively]. Here, NPPB is linked to heart failure.